Sofituzumab vedotin

Drug Profile

Sofituzumab vedotin

Alternative Names: Anti-MUC16 ADC MMAE; Anti-MUC16 mAb MMAE; Anti-MUC16 MMAE ADC; Anti-MUC16 monoclonal antibody MMAE; Anti-MUC16 monoclonal antibody monomethyl auristatin E conjugate; Anti-MUC16 monoclonal antibody vedotin; DMUC-5754A; MMAE anti-MUC16 mAb; MMAE anti-MUC16 monoclonal antibody conjugate; Monomethyl auristatin E anti-MUC16 monoclonal antibody conjugate; RG-7458; Vedotin anti-MUC16 monoclonal antibody

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 28 Jan 2015 Discontinued - Phase-I for Fallopian tube cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 28 Jan 2015 Discontinued - Phase-I for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 28 Jan 2015 Discontinued - Phase-I for Pancreatic cancer (Inoperable/Unresectable) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top